Summary of Biodesix Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $26.9 million, a 34% increase year-over-year.

Diagnostic Testing Revenue: $25.4 million, up 42% year-over-year, driven by a 38% increase in test volumes to approximately 20,900.

Gross Margin: 82%, a 200-basis-point improvement from Q2 2025.

Operating Expenses: $27.4 million, a 7% increase year-over-year, reflecting expansion of the commercial team.

Net Loss: $7.3 million, a 37% improvement compared to the prior year.

Adjusted EBITDA: Loss of $3.2 million, a 56% improvement year-over-year.

Cash Position: $30 million in unrestricted cash, a 17% increase from Q1 2026.

2Strategic Updates and Business Highlights

Continued strong growth in the diagnostic testing segment, particularly in primary care and pulmonology, with notable increases in test volumes.

The Nodify testing franchise is expanding, particularly after recent clinical publications supporting its effectiveness for smaller lung nodules.

The company is ramping up its commercial efforts, with plans to increase the sales team from approximately 104 to 120 representatives by year-end.

Ongoing operational improvements are expected to yield further efficiencies and margin enhancements.

3Forward Guidance and Outlook

Biodesix maintains its full-year revenue outlook of $108 million to $114 million, expecting continued sales productivity improvements and revenue growth.

The company anticipates sustained progress towards adjusted EBITDA profitability as the sales team gains experience.

Additional clinical publications and presentations are expected, particularly around the CHEST meeting in late October.

4Bad News, Challenges, or Points of Concern

Development services revenue decreased to $1.5 million from $2.1 million year-over-year, attributed to timing of project completion.

The company faces challenges in maintaining growth momentum against stronger year-over-year comparisons in the second half of 2025.

There is a cautious approach to expanding the sales force rapidly, balancing growth with the path to profitability.

5Notable Q&A Insights

Management expressed confidence in the continued growth of test volumes, particularly from primary care physicians (PCPs) and the positive impact of recent publications on Nodify testing.

There is a robust pipeline for contracted revenue in biopharma services, with ongoing interest following successful meetings like ASCO.

The company is focused on maintaining operational efficiencies while expanding its commercial capabilities, with a steady approach to hiring new sales representatives.

Management acknowledged the importance of upcoming guideline updates from the American College of Chest Physicians, which could significantly impact their market position. Overall, Biodesix reported strong growth in Q2 2026, driven by its diagnostic testing business, while maintaining a cautious but optimistic outlook for the remainder of the year amidst some challenges in the development services segment.